Schroder Investment Management Group Trims Stake in Jazz Pharmaceuticals PLC (JAZZ)

Schroder Investment Management Group lessened its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 34.7% during the 2nd quarter, HoldingsChannel reports. The firm owned 144,553 shares of the specialty pharmaceutical company’s stock after selling 76,747 shares during the period. Schroder Investment Management Group’s holdings in Jazz Pharmaceuticals were worth $25,132,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Tdam USA Inc. raised its holdings in Jazz Pharmaceuticals by 14.8% in the second quarter. Tdam USA Inc. now owns 2,818 shares of the specialty pharmaceutical company’s stock valued at $486,000 after acquiring an additional 363 shares in the last quarter. Xact Kapitalforvaltning AB raised its holdings in Jazz Pharmaceuticals by 2.6% in the first quarter. Xact Kapitalforvaltning AB now owns 14,606 shares of the specialty pharmaceutical company’s stock valued at $2,205,000 after acquiring an additional 374 shares in the last quarter. Adell Harriman & Carpenter Inc. raised its holdings in Jazz Pharmaceuticals by 3.0% in the second quarter. Adell Harriman & Carpenter Inc. now owns 13,790 shares of the specialty pharmaceutical company’s stock valued at $2,376,000 after acquiring an additional 400 shares in the last quarter. GAM Holding AG raised its holdings in Jazz Pharmaceuticals by 1.1% in the second quarter. GAM Holding AG now owns 38,733 shares of the specialty pharmaceutical company’s stock valued at $6,674,000 after acquiring an additional 433 shares in the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in Jazz Pharmaceuticals by 28.2% in the second quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,139 shares of the specialty pharmaceutical company’s stock valued at $369,000 after acquiring an additional 470 shares in the last quarter. 92.52% of the stock is currently owned by institutional investors and hedge funds.

JAZZ stock opened at $158.82 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.62 and a current ratio of 3.76. Jazz Pharmaceuticals PLC has a twelve month low of $128.58 and a twelve month high of $184.00. The company has a market cap of $10.16 billion, a price-to-earnings ratio of 16.66, a P/E/G ratio of 0.92 and a beta of 1.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 earnings per share for the quarter, topping analysts’ consensus estimates of $3.23 by $0.26. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. The company had revenue of $500.48 million for the quarter, compared to analysts’ expectations of $469.85 million. As a group, analysts predict that Jazz Pharmaceuticals PLC will post 11.7 earnings per share for the current year.

Several brokerages recently weighed in on JAZZ. BidaskClub cut shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, September 12th. Evercore ISI reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Friday, July 13th. Stifel Nicolaus raised their target price on shares of Jazz Pharmaceuticals from $180.00 to $205.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Leerink Swann raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, August 17th. Finally, Cantor Fitzgerald set a $203.00 target price on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 7th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $192.11.

In other news, SVP Paul Treacy sold 1,309 shares of the firm’s stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $176.61, for a total transaction of $231,182.49. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Rick E. Winningham sold 16,639 shares of the firm’s stock in a transaction that occurred on Friday, August 10th. The stock was sold at an average price of $176.18, for a total transaction of $2,931,459.02. Following the transaction, the director now owns 15,594 shares in the company, valued at $2,747,350.92. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,778 shares of company stock worth $6,011,022. 3.90% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: Moving Average – How it Helps Investors in Stock Selection

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply